Brief: Magenta Therapeutics Presents Positive MGTA-117 Clinical Data At The American Society Of Hematology Annual Meeting, Provides Program Updates

Dianthus Therapeutics

12/12/2022 22:07

Dec 12 (Reuters) - Magenta Therapeutics Inc  MGTA.O :
    * MAGENTA THERAPEUTICS PRESENTS POSITIVE MGTA-117 CLINICAL
DATA AT
THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND
PROVIDES PROGRAM UPDATES
    * MAGENTA THERAPEUTICS INC - CD45 ANTIBODY-DRUG CONJUGATE
(CD45-ADC) IND-ENABLING STUDIES ARE ADVANCING
    * MAGENTA THERAPEUTICS INC - MGTA-117 WAS WELL-TOLERATED IN
ALL
PARTICIPANTS
    * MAGENTA THERAPEUTICS INC - DATA FOR MGTA-145 CLINICAL
TRIAL FOR
STEM CELL MOBILIZATION IN SICKLE CELL DISEASE PATIENTS EXPECTED
TO BE SHARED H1 2023
    * MAGENTA THERAPEUTICS INC - PHASE 1/2 CLINICAL TRIAL IS
CURRENTLY
ENROLLING IN COHORT 4 (0.13 MG/KG)
    * MAGENTA THERAPEUTICS INC - TRANSITION TO PATIENTS WITH
TRANSPLANT-ELIGIBLE AML/MDS EXPECTED IN H1 2023 PENDING
REGULATORY ALIGNMENT
    * MAGENTA THERAPEUTICS INC - ANTICIPATES DISCLOSING CLINICAL
DATA
IN H1 2023

Source text for Eikon:  ID:nGNX2nrYfN 
Further company coverage:  MGTA.O 
 ((Reuters.Briefs@thomsonreuters.com;))